vTv Therapeutics Inc. (Nasdaq: VTVT) announced positive topline results from a placebo and active-comparator-controlled Phase 2b clinical study of TTP399 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE